SE9203753D0 - Expression system for producing apolipoprotein ai-m - Google Patents

Expression system for producing apolipoprotein ai-m

Info

Publication number
SE9203753D0
SE9203753D0 SE9203753A SE9203753A SE9203753D0 SE 9203753 D0 SE9203753 D0 SE 9203753D0 SE 9203753 A SE9203753 A SE 9203753A SE 9203753 A SE9203753 A SE 9203753A SE 9203753 D0 SE9203753 D0 SE 9203753D0
Authority
SE
Sweden
Prior art keywords
pct
apolipoprotein
expression system
sec
dna sequence
Prior art date
Application number
SE9203753A
Other languages
English (en)
Inventor
T Sejlitz
M Lake
E Holmgren
L Abrahmsen
Aa Mikaelsson
C Kalderen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9203753A priority Critical patent/SE9203753D0/sv
Publication of SE9203753D0 publication Critical patent/SE9203753D0/sv
Priority to IL10789693A priority patent/IL107896A/en
Priority to DE69328442T priority patent/DE69328442T2/de
Priority to PL93309292A priority patent/PL175955B1/pl
Priority to CZ19951487A priority patent/CZ290865B6/cs
Priority to ES94902173T priority patent/ES2146646T3/es
Priority to AU56637/94A priority patent/AU5663794A/en
Priority to AT94902173T priority patent/ATE191930T1/de
Priority to DK94902173T priority patent/DK0677109T3/da
Priority to EP94902173A priority patent/EP0677109B1/en
Priority to JP51405994A priority patent/JP3899121B2/ja
Priority to HU9501680A priority patent/HU220193B/hu
Priority to SK766-95A priority patent/SK76695A3/sk
Priority to PT94902173T priority patent/PT677109E/pt
Priority to US08/448,606 priority patent/US5721114A/en
Priority to PCT/SE1993/001061 priority patent/WO1994013819A1/en
Priority to CA002150928A priority patent/CA2150928C/en
Priority to ZA939266A priority patent/ZA939266B/xx
Priority to MX9307855A priority patent/MX9307855A/es
Priority to NO19952297A priority patent/NO319497B1/no
Priority to FI952847A priority patent/FI952847A/sv
Priority to GR20000401651T priority patent/GR3033966T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
SE9203753A 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m SE9203753D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m
IL10789693A IL107896A (en) 1992-12-11 1993-12-06 Method for the production of apoliprotein ai-m and an expression vector enabling said production
CA002150928A CA2150928C (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
JP51405994A JP3899121B2 (ja) 1992-12-11 1993-12-09 アポリポ蛋白質ａｉ−ｍを製造するための発現方式
HU9501680A HU220193B (hu) 1992-12-11 1993-12-09 Expressziós rendszer apolipoprotein AI-M előállításához
CZ19951487A CZ290865B6 (cs) 1992-12-11 1993-12-09 Expresní vektor poskytující extracelulární produkci apolipoproteinu AI-M (Milano)
ES94902173T ES2146646T3 (es) 1992-12-11 1993-12-09 Sistema de expresion que permite producir una apoliproteina ai-m.
AU56637/94A AU5663794A (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
AT94902173T ATE191930T1 (de) 1992-12-11 1993-12-09 Expressionssystem zur produktion von apolipoprotein ai-m
DK94902173T DK0677109T3 (da) 1992-12-11 1993-12-09 Ekspressionssystem til fremstilling af apolipoprotein AI-M
EP94902173A EP0677109B1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
DE69328442T DE69328442T2 (de) 1992-12-11 1993-12-09 Expressionssystem zur produktion von apolipoprotein ai-m
PL93309292A PL175955B1 (pl) 1992-12-11 1993-12-09 Wektor ekspresyjny, szczep E. coli transformowany tym wektorem oraz sposób produkcji apolipoproteiny Ai-M (Milano)
SK766-95A SK76695A3 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
PT94902173T PT677109E (pt) 1992-12-11 1993-12-09 Sistema de expressao para a producao de apoliproteina ai-m
US08/448,606 US5721114A (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein AI-M
PCT/SE1993/001061 WO1994013819A1 (en) 1992-12-11 1993-12-09 Expression system for producing apolipoprotein ai-m
MX9307855A MX9307855A (es) 1992-12-11 1993-12-10 Sistema de expresion para producir apolipotroteina ai-m.
ZA939266A ZA939266B (en) 1992-12-11 1993-12-10 Expression system for producing apolipoprotein AI-M
NO19952297A NO319497B1 (no) 1992-12-11 1995-06-09 Ekspresjonssystem for fremstilling av apolipoprotein AI-M
FI952847A FI952847A (sv) 1992-12-11 1995-06-09 Uttryckningssystem för framställning av apolipoprotein AI-M
GR20000401651T GR3033966T3 (en) 1992-12-11 2000-07-17 Expression system for producing apolipoprotein ai-m.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m

Publications (1)

Publication Number Publication Date
SE9203753D0 true SE9203753D0 (sv) 1992-12-11

Family

ID=20388112

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9203753A SE9203753D0 (sv) 1992-12-11 1992-12-11 Expression system for producing apolipoprotein ai-m

Country Status (22)

Country Link
US (1) US5721114A (sv)
EP (1) EP0677109B1 (sv)
JP (1) JP3899121B2 (sv)
AT (1) ATE191930T1 (sv)
AU (1) AU5663794A (sv)
CA (1) CA2150928C (sv)
CZ (1) CZ290865B6 (sv)
DE (1) DE69328442T2 (sv)
DK (1) DK0677109T3 (sv)
ES (1) ES2146646T3 (sv)
FI (1) FI952847A (sv)
GR (1) GR3033966T3 (sv)
HU (1) HU220193B (sv)
IL (1) IL107896A (sv)
MX (1) MX9307855A (sv)
NO (1) NO319497B1 (sv)
PL (1) PL175955B1 (sv)
PT (1) PT677109E (sv)
SE (1) SE9203753D0 (sv)
SK (1) SK76695A3 (sv)
WO (1) WO1994013819A1 (sv)
ZA (1) ZA939266B (sv)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
DE69636907T2 (de) * 1995-11-09 2007-11-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
AU1384302A (en) * 2000-11-10 2002-05-21 Proteopharma Aps Apolipoprotein analogues
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2003096983A2 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
BRPI0318046B8 (pt) 2003-01-23 2021-05-25 Esperion Therapeutics Inc compostos de hidroxila, seu usos, e composições farmacêuticas
EP1602720B1 (en) * 2003-03-05 2010-11-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing heterologous protein in e. coli
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
CN1320119C (zh) * 2004-12-09 2007-06-06 复旦大学 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法
WO2007024863A2 (en) 2005-08-22 2007-03-01 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
DE102006004871A1 (de) 2006-02-02 2007-08-09 Wacker Chemie Ag Mikroorganismenstamm zur Produktion von rekombinanten Proteinen
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
JP5394236B2 (ja) 2006-06-01 2014-01-22 インスティトュート デ カーディオロジー デ モントリオール 弁膜症治療方法及び化合物
DE502006009060D1 (de) 2006-09-22 2011-04-21 Wacker Chemie Ag Verfahren zur fermentativen Herstellung von Antikörpern
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
AU2008210586B2 (en) * 2007-01-31 2013-07-04 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
NZ579227A (en) * 2007-02-20 2012-11-30 Melior Pharmaceuticals I Inc Methods of identifying activators of lyn kinase
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
MX2009009693A (es) * 2007-07-23 2009-10-07 Melior Discovery Inc Metodos para activar irs-1 y akt.
MX2010004514A (es) * 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
CA2743139C (en) 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
KR101688547B1 (ko) 2009-02-16 2016-12-21 세레니스 쎄라퓨틱스 홀딩 에스에이 아포리포단백질 ａ-ｉ 모방체
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
DE102009053566B4 (de) 2009-11-11 2014-08-14 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mikroorganismen mit gesteigerter Sucrosemutaseaktivität
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR101967411B1 (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
MX339227B (es) * 2010-08-30 2016-05-17 Hoffmann La Roche Alimentacion alcalina.
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RS58275B1 (sr) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi i njihova proizvodnja i upotrebe
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
KR102069395B1 (ko) 2011-12-12 2020-01-22 멜리어 파마슈티칼스 아이, 인코포레이티드 제i형 및 제ii형 당뇨병의 치료
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
US10426817B2 (en) * 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
JP7182605B2 (ja) 2017-04-10 2022-12-02 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
DE3819463A1 (de) * 1988-06-08 1989-12-14 Behringwerke Ag Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
US5223407A (en) * 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
EP0497757B1 (en) * 1989-10-31 1994-06-22 Schering Corporation E. coli secretory strains
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
ES2146646T3 (es) 2000-08-16
PT677109E (pt) 2000-07-31
FI952847A0 (sv) 1995-06-09
WO1994013819A1 (en) 1994-06-23
US5721114A (en) 1998-02-24
CZ148795A3 (en) 1996-01-17
PL175955B1 (pl) 1999-03-31
CA2150928C (en) 2005-02-08
IL107896A (en) 2004-06-01
DK0677109T3 (da) 2000-07-17
HU220193B (hu) 2001-11-28
ZA939266B (en) 1994-08-08
PL309292A1 (en) 1995-10-02
NO952297D0 (no) 1995-06-09
MX9307855A (es) 1994-06-30
FI952847A (sv) 1995-06-09
IL107896A0 (en) 1994-04-12
EP0677109B1 (en) 2000-04-19
EP0677109A1 (en) 1995-10-18
SK76695A3 (en) 1996-02-07
NO952297L (no) 1995-06-09
CA2150928A1 (en) 1994-06-23
GR3033966T3 (en) 2000-11-30
DE69328442D1 (de) 2000-05-25
HUT71697A (en) 1996-01-29
NO319497B1 (no) 2005-08-22
JPH08506723A (ja) 1996-07-23
JP3899121B2 (ja) 2007-03-28
DE69328442T2 (de) 2000-09-07
AU5663794A (en) 1994-07-04
HU9501680D0 (en) 1995-08-28
ATE191930T1 (de) 2000-05-15
CZ290865B6 (cs) 2002-11-13

Similar Documents

Publication Publication Date Title
SE9203753D0 (sv) Expression system for producing apolipoprotein ai-m
ATE391782T1 (de) Inhibitor-protein des wnt-signalwegs
FI965031A (sv) Svamp med en modifierad areA-gen och en areA-gen från Aspergillus oryzae
FI954648A (sv) Separation av proteiner
DE69225221T3 (de) Fusionierte gene sowie deren verwendung zur bestimmung von metall- und xenobiotikagehalten
DK0665882T3 (da) DNA-forbindelser omfattende sekvenser kodende for mannuronan C-5-epimerase
ATE371741T1 (de) Systeme zur massenherstellung von proteinen oder peptiden durch mikroorganismen der gattung humicola
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
FI971100A0 (sv) Förfarande för framställning av rekombinant-DNA-proteiner, plasmider och modifierade celler
IT1247484B (it) Metodo per la preparazione di interleuchina 6
KR860002571A (ko) 재조합 폴리펩티드의 분리 방법
DE69309281D1 (de) Verfahren zur vernichtung von halogenkohlwasserstoffen
SE9203084D0 (sv) A new enzyme and applications thereof
ATE202798T1 (de) D-aminosäure-oxidase kodierendes dns-fragment
GB9603803D0 (en) Production of proteins, plasmids coding therefor and organisms containing such plasmids
ATE155528T1 (de) Verfahren zur herstellung rekombinanter proteine in streptomyceten
ITMI930844A1 (it) Metodo per la codifica e decodifica differenziale e relativi circuiti